BioElectronics VP of Sales Discusses Pre & Post-operative Pain Relief Surgical Program in “Stock Day” Interview

PHOENIX, April 26, 2018 -- Uptick Newswire was thrilled to have Keith Nalepka, VP of Marketing & Sales at BioElectronics (OTC Pink:BIEL) (“the Company”), return to the “Stock Day” podcast. The company has been working hard lately to expand the United Kingdom market with B. Braun in the surgical market and the product opportunity from the recent National Health Service payment approval for its ActiPatch® medical device.  

BioElectronics is with B. Braun Medical, Ltd. UK to initiate the “Total Pathways Program” program into B. Braun’s 26 geographic markets. The program is for pre-habilitation (treatment that happens prior to surgery) and post-operative recovery. This new program will benefit the majority of the 160,000 UK annual knee, hip, or joint replacements patients.  According to Keith, BioElectronics is not just trying establishing a brand, but “to establish the process to a standardize care for pre and post-operative pain.”

The company is immensely proud of their team for getting their concept through to the National Health Service (NHS) in the UK. In addition to successes here, the company is hoping to utilize their overseas success by applying data to their US-based efforts.

There are some great potential partnerships currently being discussed at BioElectronics, with the closing of a significant deal just on the horizon.

BioElectronics Corp is approaching their upcoming FDA meetings with confidence. “We have the data to make a very strong case for both broader musculoskeletal and post-operative pain relief indications,” said Nalepka. “It’s an exciting time for the company, and a really cool little product.”

For more details on the Total Pathways Program, news about a partnerships, and information about the company’s upcoming meetings with the FDA, follow the link below to the full interview.

https://upticknewswire.com/wp-content/uploads/2018/04/Uptick-Network-BIEL-Interview-4-25-18.mp3

About BioElectronics

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.

Contact: Paul Knopick, 940.262.3584, [email protected]

Safe Harbor Statement

Certain statements contained herein are “forward-looking statements,” (as defined in the Private Securities Litigation Reform Act of 1995). BioElectronics Corp. cautions that statements and assumptions made in this news release constitute forward-looking statements; the company makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, and other estimates made by management. Actual results could differ from current projections or implied results. BioElectronics Corp. undertakes no obligation to revise these statements following the date of this news release.

About Uptick Newswire

Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.

Contact Information

Uptick Newswire LLC 
Everett Jolly, CEO/Founder 
602-441-3474 
10000 N. 31st Avenue C307 Phoenix, AZ 85051 
[email protected]
www.upticknewswire.com